Future directions include combinatorial clinical trials should evaluate the efficacy of topical or intralesional antifibrotics, RNA-based agents, and TGF-β inhibitors in patients with lichenified AD or tunnel-forming HS. The gene discussed is TGFB1; the disease is Alzheimer disease.